A detailed history of Braidwell LP transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Braidwell LP holds 34,094 shares of VRDN stock, worth $580,279. This represents 0.04% of its overall portfolio holdings.

Number of Shares
34,094
Holding current value
$580,279
% of portfolio
0.04%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$17.85 - $25.71 $608,577 - $876,556
34,094 New
34,094 $653,000
Q4 2023

Feb 14, 2024

SELL
$11.12 - $22.5 $15.7 Million - $31.8 Million
-1,412,080 Reduced 81.38%
323,102 $7.04 Billion
Q3 2023

Nov 14, 2023

BUY
$15.16 - $24.7 $8.02 Million - $13.1 Million
528,882 Added 43.84%
1,735,182 $26.6 Billion
Q2 2023

Aug 14, 2023

BUY
$22.57 - $29.67 $27.2 Million - $35.8 Million
1,206,300 New
1,206,300 $28.7 Billion
Q4 2022

Feb 14, 2023

BUY
$18.78 - $29.74 $5.89 Million - $9.32 Million
313,403 New
313,403 $9.15 Billion

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $679M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Braidwell LP Portfolio

Follow Braidwell LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Braidwell LP, based on Form 13F filings with the SEC.

News

Stay updated on Braidwell LP with notifications on news.